Drugs / PfCP2.9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00284973 | Jan 2006 → ? | Plasmodium falciparum malaria | Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfCP-2.9 | “Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide...” NCT00284973 ↗1“one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720” NCT00284973 ↗ |
| Known as | AMA-1/MSP-1 Recombinant Malaria Vaccine | “Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide...” NCT00284973 ↗ |
| Modality | Vaccine | “one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720” NCT00284973 ↗ |